Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company's lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The compa… Read more
Dextech Medical AB (LQ0) - Total Liabilities
Latest total liabilities as of September 2025: €-510.00K EUR
Based on the latest financial reports, Dextech Medical AB (LQ0) has total liabilities worth €-510.00K EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dextech Medical AB - Total Liabilities Trend (2022–2025)
This chart illustrates how Dextech Medical AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dextech Medical AB Competitors by Total Liabilities
The table below lists competitors of Dextech Medical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aqua Bio Technology ASA
OL:ABTEC
|
Norway | Nkr177.25 Million |
|
Vape Holdings Inc
NASDAQ:VAPE
|
USA | $1.23 Million |
|
Focus Dynamics Group Bhd
KLSE:0116
|
Malaysia | RM123.97 Million |
|
AddTech Hub Public Company Limited
BK:ADD
|
Thailand | ฿108.35 Million |
|
Bd Multimedia
PA:ALBDM
|
France | €2.94 Million |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
India | ₹206.50 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Dextech Medical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 43.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | -0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dextech Medical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dextech Medical AB (2022–2025)
The table below shows the annual total liabilities of Dextech Medical AB from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €336.85K | -65.64% |
| 2024-06-30 | €980.31K | +36.49% |
| 2023-06-30 | €718.22K | +0.91% |
| 2022-06-30 | €711.77K | -- |